Drug
Enfortumab vedotin clinical trials
Also written ASG-22CE, Padcev and AGS-22M6E.
- studies test it
- 59
- open now
- 37
- in phase 3
- 6
- first study started
- 2011
Keep track of what changes. Save the enfortumab vedotin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
58 studies that test it; most in 2025 (14); 1 more planned to start later
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2014 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 5 |
| 2023 | 6 |
| 2024 | 5 |
| 2025 | 14 |
| 2026 | 14 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 17
- Phase 2
- 41
- Phase 3
- 6
- Phase 4
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 24 · Other 35
Astellas Pharma Global Development, Inc. (7) · Memorial Sloan Kettering Cancer Center (3) · Merck Sharp & Dohme LLC (3) · Astellas Pharma Inc (3) · Mayo Clinic (3) · National Cancer Institute (NCI) (2) · University of Utah (2) · Emory University (2)
Often tested with
Tested in the same studies.
Pembrolizumab (26) · Sacituzumab govitecan (5) · Trastuzumab deruxtecan (3) · Cisplatin (2) · Avelumab (2) · Gemcitabine (2) · Datopotamab deruxtecan (2) · Erdafitinib (1)
Studies
Open first, then newest update. How each study uses enfortumab vedotin is read from its arms, and is right about nine times in ten.
Testing it · 59
- Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial CancerRecruitingPhase 1/2Fred Hutchinson Cancer CenterNCT07667335Written as Enfortumab Vedotin
- A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their BladderRecruitingPhase 2Astellas Pharma Global Development, Inc.NCT07475806Written as Enfortumab Vedotin
- A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]RecruitingPhase 1/2Daiichi SankyoNCT07890714Written as Enfortumab Vedotin (EV)
- Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06311214Written as Enfortumab Vedotin
- Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)RecruitingPhase 3Astellas Pharma Global Development, Inc.NCT07566156Written as Enfortumab vedotin
- Study of EV for Recurrent Endometrial CarcinomaRecruitingPhase 2William BradleyNCT07139977Written as Enfortumab Vedotin
- Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial CancerRecruitingPhase 1Generate BiomedicinesNCT07484022Written as enfortumab vedotin (EV)
- DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile CarcinomaRecruitingPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT07110038Written as enfortumab vedotin
- Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial CancerRecruitingPhase 1/2PfizerNCT07421700Written as Enfortumab Vedotin
- Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT CarcinomaNot yet recruitingPhase 2Northwestern UniversityNCT07863765Written as Enfortumab Vedotin
- Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder CancerRecruitingPhase 1/2University of California, San FranciscoNCT06470282Written as Enfortumab Vedotin
- Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI TrialRecruitingPhase 4Mayo ClinicNCT06764095Written as Enfortumab Vedotin
- A Study of Enfortumab Vedotin in People With Adenoid Cystic CarcinomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06891560Written as Enfortumab Vedotin
- Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder CancerRecruitingPhase 1/2University of Texas Southwestern Medical CenterNCT06394570Written as Enfortumab vedotin
- N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial CancerNot yet recruitingPhase 1ImmunityBio, Inc.NCT07217496Written as enfortumab vedotin (EV)
- Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07825753Written as Enfortumab vedotin (EV)
- A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial CancerNot yet recruitingPhase 2University of UtahNCT07822373Written as Enfortumab vedotin
- A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial CancerRecruitingPhase 4Astellas Pharma Global Development, Inc.NCT06862219Written as Enfortumab Vedotin
- Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder CancerRecruitingPhase 2Matthew GalskyNCT06809140Written as Enfortumab vedotin
- Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant HistologyRecruitingPhase 2Emory UniversityNCT05756569Written as Enfortumab Vedotin
See all 59 studies that test enfortumab vedotin →
Given in every arm · 14 — enfortumab vedotin is usual care beside what is tested
- A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid TumorsRecruitingPhase 1/2Astellas Pharma Global Development, Inc.NCT07287995Written as Enfortumab Vedotin
- A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial CarcinomaRecruitingPhase 2/3Summit TherapeuticsNCT07815665Written as enfortumab vedotin (EV)
- FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3RecruitingPhase 1Eli Lilly and CompanyNCT05614739Written as enfortumab vedotin
- Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)RecruitingPhase 2National Cancer Institute (NCI)NCT06041503Written as Enfortumab vedotin
- Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBCNot yet recruitingPhase 2The Netherlands Cancer InstituteNCT07663747Written as Enfortumab Vedotin
- Sacituzumab Govitecan Plus EV in Metastatic UCRecruitingPhase 1/2Dana-Farber Cancer InstituteNCT04724018Written as Enfortumab vedotin-ejfv (EV)
- Probiotics in Advanced Urothelial CarcinomaRecruitingPhase 2Sun Yat-sen UniversityNCT06904573Written as Enfortumab Vedotin
- A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)Active, not recruitingPhase 2Astellas Pharma Global Development, Inc.NCT04225117Written as enfortumab vedotin
- Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent StudyCompletedPhase 2/3Mirati Therapeutics Inc.NCT04887870Written as Enfortumab Vedotin-Ejfv
- A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial CancerTerminatedPhase 1/2Astellas Pharma Global Development, Inc.NCT03288545Written as enfortumab vedotin (EV)
- Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial CarcinomaActive, not recruitingPhase 2Fox Chase Cancer CenterNCT05923190Written as Enfortumab vedotin
- A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)Active, not recruitingPhase 1/2Merck Sharp & Dohme LLCNCT06483334Written as Enfortumab Vedotin
- A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)Active, not recruitingPhase 1/2Merck Sharp & Dohme LLCNCT05845814Written as EV
- A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial CarcinomaTerminatedPhase 2Mirati Therapeutics Inc.NCT03606174Written as Enfortumab vedotin
As the comparator · 2 — what is tested is compared with enfortumab vedotin
- An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUCRecruitingPhase 3AstraZenecaNCT07720284Written as Enfortumab vedotin
- Modular Trial of sEphB4-HSA in EphrinB2-High Solid TumorsRecruitingPhase 2/3Vasgene Therapeutics, IncNCT06493552Written as Enfortumab vedotin
Codes
What other systems call enfortumab vedotin · ClinicalTrials.gg INT001132
- MeSH (NLM) C000632577enfortumab vedotinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) DLE8519RWMENFORTUMAB VEDOTINConfirmed FDA, NLM, Wikidata
- RxNorm 2268306One source FDA
- Wikidata Q19904068enfortumab vedotinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C114500Enfortumab VedotinOne source FDA
- DrugBank DB13007One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000632577 | enfortumab vedotin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | DLE8519RWM | ENFORTUMAB VEDOTIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2268306 | — | One source FDA |
| Wikidata | Q19904068 | enfortumab vedotin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C114500 | Enfortumab Vedotin | One source FDA |
| DrugBank | DB13007 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.